References
- Doody R, Dunn, J, Clark et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease Dement. Ceriatc Cogn. Disord.12, 295–230, (2001).
- MacGowan S. Wilcock G, Scott M. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int.j Geriatric fiych. 13,625–630 (1998).
- Raskind M, Peskind E, Wessel T Galantamine in Alzheimer's disease: a 6 month randomised placebo-controlled trial with a 6 month extension. Neurology 54,2261–2268 (2000).
- Harrington F, Saxby BK, McKeith IG, Wesnes K, Ford GA. Cognitive performance in hypertensive and normotensive older subjects. Hypertension 36,1079–1082(2000).
- Alves De Moraes S, Szldo M, Knopman D, Sato R. The relationship between temporal changes in blood pressure and changes in cognitive function: atherosclerosis risk in communities (ARIC) study. Preventative Med. 35,258–263 (2002).
- Forette F, Seux ML, Staessen JA et al The prevention of dementia with antihypertensive treatment. Arch Intern. Med. 162(18), 2046–2052 (2002).
- Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Anil Intern. Med163(9), 1069–1075 (2003).
- Chalmers J, MacMahon S, Cooper M et al Rationale and design of the ADVANCE study: a randomized trial of blood pressure lowering and intensive glucose control in high risk individuals with Type 2 diabetes mellitus. J. Hypertens. 19, S21—S28 (2001).
- Dahlof B, Keller S, Makris L, Goldberg A, Sweet C, Lim N. Efficacy and tolerability of losartan potassium and atenolo in patients with mild to moderate essential hypertension. A117. I Hypertens. 8,578-583 (1995).
- Yusef S. From HOPE to the ONTARGET and TRANSCEND studies: challenges in improving prognosis. Am. J. Carcliol 89, A18—A25 (2002).
- Semplicini A, Maresca A, Sartori M, Cabo L, Pessina AC. Hypertension and cerebrovascular diseases: a specific role of vascular protection for the prevention of dementia. J. Canliovasc. Phatmacol 38, S79—S82 (2001).
- ••Excellent summary of current opinion asto the role of vascular factors in dementia.
- Farkas E, De Vos RAI, Jansen-Steur ENH, Luiten PGM. Are Alzheimer's disease, hypertension and cerebrocapillary damage related? Neurobial Aging21, 235–243 (2000).
- Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio E Protective effect of antihypertensive treatment on cognitive function in essential hypertension: Analysis of published clinical data. J. Neural Sci 203,147–151 (2002).
- •General overview of studies which have considered cognitive effects of antihypertensives.
- Starr JM, Whalley LJ, Deary IJ. The effect of antihypertensive treatment on cognitive function: results from the HOPE study. J. Amer Ceriatc Soc. 44,411-415 (1996).
- Forette F, Seux M, Staessen J, Thijs L, Birkenhager W Prevention of dementia in randomized double-blind placebo-controlled systolic hypertension in Europe (Sys-Eur) trial. Lancet 352,1347–1351 (1998).
- Skoog I. Vascular aspects in Alzheimer's disease. J. Neural. 71ansm. 59,3-43 (2000).
- Kalaria RN. The role of cerebral ischaemia in Alzheimer's disease. Neurobial Aging21, 321–330 (2000).
- ••Excellent review.
- Atkinson J. Cerebrovascular structure and dementia: new drug targets. Trends Pharmacol Li. 22,630–635 (2001).
- De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger, T International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharm. Rev 52,415–472 (2000).
- ••Definitive review of the differentproperties and actions of the angiotensin receptors.
- Albiston AL, McDowall SG, Matsacos D et al. Evidence that the angiotensin IV (ATLI) receptor is the enzyme insulin regulated aminopeptidase. j Biol. Chem. 276,48623–48626 (2001).
- •First evidence of the nature of the angiotensin Type 4 receptors.
- Vauguelin G, Michotte Y, Smolders I et al. Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. JR4AS3, 195–204 (2002).
- ••Interesting review of the roles ofangiotensin fragments, in particular angiotensin IV.
- Wright JW, Harding JW. Important roles for angiotensin III and IV in the brain renin—angiotensin system. Brain Res. Rev 25,96–124 (1997).
- Gard PR. The role of angiotensin in cognition and behaviour. Eur. j Pharmacol 438 1–14 (2002).
- ••Reviews the recent evidence thatangiotensin plays a role in the control of mood and cognition.
- Raghavendra V, Chopra K, Kulkarni SK. Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory. Neuropeptides 32,417–421 (1998).
- Horiuchi M, Lehtonen, JYA, Davlet L. Signaling mechanism of the AT2 angiotensin II receptor: crosstalk between AT1 and AT2 receptors in cell growth. Bends Endocrinal Metab. 10,391–396 (1999).
- Hilscher C. Long-term potentiation: a good model for learning and memory?Prog. Neumpsychophatmacol Biol. fiychtry 21, 47–68 (1997).
- von Bohlen und Halbach O, Albrecht D, Halbach OVU. Angiotensin II inhibits long-term potentiation within the lateral nucleus of the amygdala through AT(1) receptors. Peptides 19,1031–1036 (1998).
- Lee J, Chai S-Y, Mendelsohn FAO, Morris MJ, Allen AM. Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LW-hemorphin-7. Neumphalmacology 40, 618–623 (2001).
- Tracy HA, Wayner MJ, Armstrong DL. Losartan improves the performance of ethanol-intoxicated rats in an eight-arm maze. Alcohol14, 511–517 (1997).
- Orgogozo, J. New millennium: new expectations for Alzheimer's disease. Dement. Ceriatc Cogn. Disonl 11,1–2 (2000).
- •Commentates on the issues around drug treatments for dementia: emphasis on cholinomimetics.
- Weiner MF, Bonte FJ, Tintner R, Ford N, Svetlik D, Riall T ACE inhibitor lacks acute effect on cognition or brain blood-flow in Alzheimer's disease. Drug- Devel Res. 26,467–471 (1992).
- Louis WJ, Mander AG, Dawson M, O'Callaghan C, Conway EL. Use of computerised neuropsychological test (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly. J. Hypertens. 17,1813–1819 (1999).
- Sudilovsky A, Cutler NR, Sramek, JJ et al A pilot clinical-trial of the angiotensin-converting enzyme-inhibitor ceranapril in Alzheimer's-disease. Alzheimer Dis. Assoc. Disord 7,105–111 (1993).
- ••Earliest investigation of the effects of ACE inhibitors on cognition in humans.
- Tedesco MA, Ratti G, Mennella S et al Comparison of losartan and hydrochlorthiazide on cognitive function and quality of life in hypertensive patients. Am. Hypertens. 12,1130–1134 (1999).
- ••Important evidence that MIA may bemore effective than angiotensin converting enzyme inhibitors in the moderation of cognition.
- Fogari R, Preti P, Mugellini A et al Influence of Losaratan and Atenolol on cognitive function in very elderly hypertensive patients. Am. j Hypertens. 15, 4,36A (2002).
- •Provides further evidence of a positive effect of losartan in cognition.
- Ge JA, Barnes NM. Alterations in angiotensin ATI and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Eur. Pharmacol 297,299–306 (1996).
- Savaskan E, Hock C, Olivieri G et al. Cortical alterations of Angiotensin converting enzyme, angiotensin II and ATI receptor in Alzheimer's dementia. Neurobial Aging22, 541–546 (2001).
- Rieder MJ, Taylor SL, Clark AG, Nickerson DA. Sequence variation in the human angiotensin converting enzyme. Nature Genet. 22,59–62 (1999).
- Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier E An insertion/deletion polymorphism of the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. j Gun. Invest. 86, 1343–1346 (1990).
- Staessen JA, Ginocchio G, Wang JG et al. Genetic variability in the renin—angiotensin system: prevalence of alleles and genotypes. I Carcliovasc. Risk 4,401–422 (1997).
- Frederiksen H, Gaist D, Bathum L et al. Angiotensin I-converting enzyme (ACE) gene polymorphism in relation to physical performance, cognition and survival: a follow-up study of elderly Danish twins. Ann. Epiclemial 13,57–65 (2003).
- Konings CH, Kuiper MA, Scheltens P, Grijma AM, Vanpelt W, Wolters EC. Reevaluation of cerebrospinal fluid angiotensin-converting enzyme activity in patients with probable Alzheimer's disease. Eur j Gun. Chem. Gun. Biochem. 31, 495–497 (1993).
- Monastero R, Caldarella R, Mannino M et al Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer's disease. Neumsci. Lett. 335,147–149 (2002).
- Wakutani Y, Kowa H, Kusumi M. Genetic analysis of vascular factors in Alzheimer's disease. Alz. Dis. Vasc.Pathol 977,232–238 (2002).
- Agachan B, Yilmaz H, Aydin M, Isbir T Is there any association between apolipoprotein E and angiotensin converting enzyme gene polymorphism in patients with Parkinson's disease and dementia in Turkish Population?Neurosci. Res. Comm. 27,165–173 (2000).
- Farrer LA, Sherbatich T, Keryanov SA et al Association between angiotensin-converting enzyme and Alzheimer's disease. Arch. Neural. 57,210–214 (2000).
- Chapman J, Wang NS, Treves TA, Korczyn AD, Bornstein NM. ACE, MTHFR, Factor V Leiden and APOE polymorphisms in patients with vascular and Alzheimer's dementia. Stroke 29,1401–1404 (1998).
- Scacchi R, Bernardini L, Mantuano E et al DNA polymorphisms of apolipoprotein B and angiotensin I-converting enzyme genes and relationships with lipid levels in Italian patients with vascular dementia or Alzheimer's disease. Dement. Geriatr Cogn. Disarl. 9,186–190 (1998).
- Tysoe C, Galinsky D, Robinson D et al Analysis of a-1 antichymotrypsin, presenilin-1, angiotensin-converting enzyme and methylenetetrahydrofolate reductase loci as candidates for dementia. Am.j Merl Genet. 74,207-212 (1997).
- Lendon CL, Thaker U, Harris JM et al The angiotensin I-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease. Neurosci. Lett. 328, 314–318 (2002).
- Myllykangas L, Polvikoski T, Sulkava R et al Cardiovascular risk factors and Alzheimer's disease: a genetic association study in a population aged 85 or over. Neurosci. Lett. 292,195-198 (2000).
- McGeer EG, Singh EA. Angiotensin converting enzyme in cortical tissue in Alzheimer's and some other neurological diseases. Dementia 3,299–303 (1992).
- Palumbo B, Cadini D, Nocentini G, Filipponi E, Fravolini ML, Senin U. Angiotensin converting enzyme deletion allele in different kinds of dementia disorders. Neurosci. Lett. 267,97–100 (1999).
- Seripa D, Dal Forno G, Matera MG et al Methylenetetrahydrofolate reductase and angiotensin converting enzyme gene polymorphisms in two genetically and diagnostically distinct cohort of Alzheimer patients. Neurobial Aging (2003) (In Press).
- Richard F, Fromentin-David I, Ricolfi F et al The angiotensin I converting enzyme gene as a susceptibility factor for dementia. Neurology56, 1593–1595 (2001).
- •Evidence for a positive relation with cognitive decline.
- Yang JD, Feng GY, Zhang J et al. Association between angiotensin-converting enzyme gene and late onset Alzheimer's disease in Han Chinese. Neurosci. Lett. 295,41–44 (2000).
- Cheng C-Y, Hong C-J, Liu H-C, Liu T-Y, Tsai S-J. Study of the association between Alzheimer's disease and angiotensin-converting enzyme gene polymorphism using DNA from lymphocytes. Eur Neural. 47,26–29 (2002).
- Hu CJ, Sung SM, Liu HC et al No association of a-2 macroglobulin gene five-nucleotide deletion with AD in Taiwan Chinese. Neurology53, 642–643 (1999).
- Alvarez R, Alvarez V, Lahoz CH et al. Angiotensin converting enzyme and endothelial nitric oxide synthase DNA polymorphisms and late onset Alzheimer's disease. .1. Neural. Neurosurg. fiychiatry67, 733–736 (1999).
- Matilla KM, Rinne JO, Roytta M et al. Dipeptidykarboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon 4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer's pathology. j Med. Genet. 37,766-770 (2000).
- Richard F, Berr C, Amant C, Helbecque N, Amouyel P, Alperovitch A. The EVA Study Group. Effect of angiotensin I-converting enzyme I/D polymorphism on cognitive decline. Neurobia Aging 21, 75–80 (2000).
- Bartres-Faz D, Junque C, Clemente IC et al Relationship among H-1-magnetic resonance spectroscopy, brain volumetry and genetic ppolymorphisms in humans with memory impairment. Neurosci. Lett. 327,177-180 (2002).
- Narain Y, Yip A, Murphy T et al. The ACE gene and Alzheimer's disease susceptibility. .1. Merl Genet. 37,695-697 (2000).
- Crawford F, Adbullah L, Schinka J et al Gender-specific association of the angiotensin converting enzyme gene with Alzheimer's disease. Neurosci. Lett. 280, 215–219 (2000).
- Amouyel P, Richard F, Ben C, David- Fromentin I, Helbecque N. The renin angiotensin system and Alzheimer's disease. Vasc. Factors. Alzheimels clis. 903, 437–441 (2000).
Website
- Gard PR, Goldhill J. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Lead Disco veiy Dossier (2002) www.leaddiscovery.co.uk/reports-angiotensin.html (Accessed October 2003)